23-valent pneumococcal polysaccharide vaccine. WHO position paper

Wkly Epidemiol Rec. 2008 Oct 17;83(42):373-84.
[Article in English, French]
No abstract available

MeSH terms

  • Adult
  • Aged
  • Cost-Benefit Analysis
  • Disease Outbreaks / prevention & control
  • Humans
  • Infant
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / adverse effects
  • Pneumococcal Vaccines / economics
  • Pneumococcal Vaccines / therapeutic use*
  • Streptococcus pneumoniae

Substances

  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Pneumococcal Vaccines